[{"orgOrder":0,"company":"Fudan University","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fudan University \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Fudan University \/ Novo Nordisk"},{"orgOrder":0,"company":"Centre Europ\u00e9en d'\u00c9tude du Diab\u00e8te","sponsor":"Novo Nordisk | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Centre Europ\u00e9en d'\u00c9tude du Diab\u00e8te","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Europ\u00e9en d'\u00c9tude du Diab\u00e8te \/ Novo Nordisk | Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Centre Europ\u00e9en d'\u00c9tude du Diab\u00e8te \/ Novo Nordisk | Abbott Laboratories"},{"orgOrder":0,"company":"Buckinghamshire Healthcare NHS Trust","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Buckinghamshire Healthcare NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Buckinghamshire Healthcare NHS Trust \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"Buckinghamshire Healthcare NHS Trust \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"University of Colorado, Denver \/ Novo Nordisk"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vanderbilt University \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Vanderbilt University \/ Novo Nordisk"},{"orgOrder":0,"company":"Diabetes Care Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Insulin Detemir","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Diabetes Care Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diabetes Care Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Diabetes Care Center \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Insulin Detemir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 18, 2017

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 12, 2014

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 04, 2013

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Centre Européen d'Étude du Diabète

                          Country arrow
                          CPhI India
                          Not Confirmed

                          Centre Européen d'Étude du Diabète

                          Country arrow
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          April 11, 2013

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase IV

                          Sponsor : Novo Nordisk | Abbott Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 18, 2012

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 02, 2012

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 02, 2012

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 26, 2011

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 26, 2011

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPhI India
                          Not Confirmed
                          CPhI India
                          Not Confirmed

                          Details : Insulin Detemir is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 22, 2011

                          Lead Product(s) : Insulin Detemir

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank